- An increasing number of scientists now realize the limitations of gene-sequencing in clinical diagnostics, opening an opportunity for growth, highlighted by the rising number of Saphyr mentions in academic publications.
- Recent technological advancements in the gene-editing arena bode well for BNGO's market. Such developments include approvals of gene therapies and the discovery of CRISPR.
- The recent surge in BNGO's share provides relief from the financial burdens, allowing management to enhance its product offerings.
For further details see:
Bionano Genomics' Second Chance